Factor V Leiden Mutation and its Impact on Pregnancy Complications

Hammerova, L.; Chabada, J; Drobny, J; Bátorová, Angelika

doi:10.14712/18059694.2016.32

Cited by 4 publications

(3 citation statements)

References 38 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, other studies described no increased risk of fetal loss in women with the factor V Leiden mutation compared to those without [10,91,92]. A larger study, [93,94] found a similar prevalence of factor V Leiden in patients with first and second trimester losses compared to a control group of parous women.…”

Section: Factor V Leiden and Obstetric Outcomementioning

confidence: 89%

“…A more recent prospective observational study found that heterozygous carriers of the factor V Leiden mutation did not display increased odds of pre-eclampsia, intrauterine death, placental abruption or venous thrombo-embolism. However, almost 50% of the patients within this study were treated with heparin and this could have modulated the results [93,94].…”

Section: Factor V Leiden and Obstetric Outcomementioning

confidence: 96%

See 1 more Smart Citation

Pregnancy and Thrombophilia

Dawood

2013

J Blood Disord Transfus

View full text Add to dashboard Cite

Thrombophilic disorders encompass a diverse group of coagulation disorders that potentiate a predisposition for thrombotic events. Amongst the known thrombophilias are antithrombin III deficiency, prothrombin G20210A gene mutation, protein S and protein C deficiency, activated protein C resistance and the antiphospholipid syndrome. Thrombophilia and its influence on pregnancy have been studied for the past 50 years. Both inherited and acquired thrombophilia have been associated with an increased risk of thrombo-embolism as well as an increased risk of pregnancy loss and adverse obstetric outcomes. Some thrombophilias (antiphosphoplipid syndrome, factor V Leiden mutation and antithrombin III deficiency confer a higher risk of both venous thrombo-embolism and obstetric complications. There is still no consensus on the optimal management of thromboprophylaxis in future pregnancies. Clearly large well designed and adequately powered multicenter randomised trials are required to clarify the management of thrombophilia in pregnancy especially with a history of adverse obstetric outcome.

show abstract

Section: Factor V Leiden and Obstetric Outcomementioning

confidence: 89%

Section: Factor V Leiden and Obstetric Outcomementioning

confidence: 96%

Pregnancy and Thrombophilia

Dawood

2013

J Blood Disord Transfus

View full text Add to dashboard Cite

show abstract

“…Space limitations prevented us from more detailed reporting of the methods and results of our systematic review. We are familiar with the study by Kjellberg et al ., as it was one of the seven full‐text articles that were retrieved in the systematic review process. Their report was independently assessed by two reviewers (M.R.…”

mentioning

confidence: 99%

Is thrombophilia associated with placenta‐mediated pregnancy complications? A prospective cohort study: reply

Rodger

Langlois

2015

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

We thank Drs Kjellberg and Hellgren for their letter and for pointing our that the results of their study are consistent with our findings. Space limitations prevented us from more detailed reporting of the methods and results of our systematic review. We are familiar with the study by Kjellberg et al., as it was one of the seven full-text articles [1][2][3][4][5][6][7] that were retrieved in the systematic review process. Their report was independently assessed by two reviewers (M.R. and N.L.) and then discussed, leading to the conclusion that the study was not eligible, owing to its design. That is, the 'case-cohort' design did not meet the first of three eligibility criteria that were established a priori for our meta-analysis; studies had to enroll unselected pregnant women in the first or second trimester of pregnancy. Although 6003 women were screened for their study, 'every fifth woman who tested negative for activated protein C resistance was selected as a control'.Although this study could not be included in our formal meta-analysis, we agree with the comments of Kjellberg and Hellgren that the consistency of the findings between their study and ours lends additional support for the conclusion that an association does not exist between the factor V Leiden mutation or the prothrombin gene mutation and placenta-mediated pregnancy complications.It is also worth pointing out that the proportion of small-for-gestational-age children is a more clinically relevant outcome than mean differences in birth weight between exposed and unexposed groups. One could imagine scenarios where there are no mean differences between two exposed groups, yet the exposure leads to severe small for gestational age birth in an important proportion of patients without significantly influencing the mean birth weight in the exposed group.

show abstract

Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis

Croles¹,

Nasserinejad²,

Duvekot

et al. 2017

BMJ

115

View full text Add to dashboard Cite

Objective To provide evidence to support updated guidelines for the management of pregnant women with hereditary thrombophilia in order to reduce the risk of a first venous thromboembolism (VTE) in pregnancy. Design Systematic review and bayesian meta-analysis. Data sources Embase, Medline, Web of Science, Cochrane Library, and Google Scholar from inception through 14 November 2016. Review methods Observational studies that reported on pregnancies without the use of anticoagulants and the outcome of first VTE for women with thrombophilia were eligible for inclusion. VTE was considered established if it was confirmed by objective means, or when the patient had received a full course of a full dose anticoagulant treatment without objective testing. Results 36 studies were included in the meta-analysis. All thrombophilias increased the risk for pregnancy associated VTE (probabilities ≥91%). Regarding absolute risks of pregnancy associated VTE, high risk thrombophilias were antithrombin deficiency (antepartum: 7.3%, 95% credible interval 1.8% to 15.6%; post partum: 11.1%, 3.7% to 21.0%), protein C deficiency (antepartum: 3.2%, 0.6% to 8.2%; post partum: 5.4%, 0.9% to 13.8%), protein S deficiency (antepartum: 0.9%, 0.0% to 3.7%; post partum: 4.2%; 0.7% to 9.4%), and homozygous factor V Leiden (antepartum: 2.8%, 0.0% to 8.6%; post partum: 2.8%, 0.0% to 8.8%). Absolute combined antepartum and postpartum risks for women with heterozygous factor V Leiden, heterozygous prothrombin G20210A mutations, or compound heterozygous factor V Leiden and prothrombin G20210A mutations were all below 3%. Conclusions Women with antithrombin, protein C, or protein S deficiency or with homozygous factor V Leiden should be considered for antepartum or postpartum thrombosis prophylaxis, or both. Women with heterozygous factor V Leiden, heterozygous prothrombin G20210A mutation, or compound heterozygous factor V Leiden and prothrombin G20210A mutation should generally not be prescribed thrombosis prophylaxis on the basis of thrombophilia and family history alone. These data should be considered in future guidelines on pregnancy associated VTE risk.

show abstract

Factor V Leiden Mutation and its Impact on Pregnancy Complications

Cited by 4 publications

References 38 publications

Pregnancy and Thrombophilia

Pregnancy and Thrombophilia

Is thrombophilia associated with placenta‐mediated pregnancy complications? A prospective cohort study: reply

Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and bayesian meta-analysis

Contact Info

Product

Resources

About